Search Results - Aleksandr Suvorov

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

    Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study by Meletios Α. Dimopoulos, A. Keith Stewart, Tamás Masszi, Ivan Špıčka, Albert Oriol, Roman Hájek, Laura Rosiñol, David S. Siegel, Georgi Mihaylov, Vesselina Goranova‐Marinova, Péter Rajnics, Aleksandr Suvorov, Rubén Niesvizky, Andrzej Jakubowiak, Jesús F. San Miguel, Heinz Ludwig, Antonio Palumbo, Mihaela Obreja, Sanjay Aggarwal, Philippe Moreau

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

    Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment by Meletios Α. Dimopoulos, A. Keith Stewart, Tamás Masszi, Ivan Špıčka, Albert Oriol, Roman Hájek, Laura Rosiñol, David S. Siegel, Georgi Mihaylov, Veselina Goranova‐Marinova, Péter Rajnics, Aleksandr Suvorov, Rubén Niesvizky, Andrzej Jakubowiak, Jesús F. San Miguel, Heinz Ludwig, Sunhee Ro, Sanjay Aggarwal, Philippe Moreau, Antonio Palumbo

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

    Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial by Ruben A. Mesa, Alessandro M. Vannucchi, Adam J. Mead, Miklós Egyed, Anita Szőke, Aleksandr Suvorov, János Jakucs, Andrew C. Perkins, Ritam Prasad, Jiřı́ Mayer, Judit Demeter, Peter Ganly, Jack W. Singer, Huafeng Zhou, James P. Dean, Peter A. te Boekhorst, Jyoti Nangalia, Jean‐Jacques Kiladjian, Claire Harrison

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

    Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study by Philippe Moreau, D. Joshua, W-J Chng, Antonio Palumbo, Hartmut Goldschmidt, Roman Hájek, Thierry Façon, Heinz Ludwig, Luděk Pour, Rubén Niesvizky, Albert Oriol, Laura Rosiñol, Aleksandr Suvorov, Gianluca Gaïdano, Tomáš Pika, Katja Weisel, Veselina Goranova‐Marinova, H H Gillenwater, Nehal Mohamed, Sanjay Aggarwal, Shibao Feng, Meletios Α. Dimopoulos

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

    Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR by W-J Chng, Hartmut Goldschmidt, Meletios Α. Dimopoulos, Philippe Moreau, D. Joshua, Antonio Palumbo, Thierry Façon, H. Ludwig, Luděk Pour, Rubén Niesvizky, Albert Oriol, Laura Rosiñol, Aleksandr Suvorov, Gianluca Gaïdano, Tomáš Pika, Katja Weisel, Veselina Goranova‐Marinova, H. H. Gillenwater, Nehal Mohamed, Shibao Feng, Shyam Aggarwal, Roman Hájek

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

    Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma by A. Keith Stewart, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Tamás Masszi, Ivan Špıčka, Albert Oriol, Roman Hájek, Laura Rosiñol, David S. Siegel, Georgi Mihaylov, Vesselina Goranova‐Marinova, Péter Rajnics, Aleksandr Suvorov, Rubén Niesvizky, Andrzej Jakubowiak, Jesús F. San Miguel, Heinz Ludwig, Michael Wang, Vladimír Maisnar, Jiří Minařík, William Bensinger, María-Victoria Mateos, Dina Ben‐Yehuda, Vishal Kukreti, Naseem J. Zojwalla, Margaret Tonda, Xinqun Yang, Biao Xing, Philippe Moreau, Antonio Palumbo

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicent... by Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo, Douglas Joshua, Luděk Pour, Roman Hájek, Thierry Façon, Heinz Ludwig, Albert Oriol, Hartmut Goldschmidt, Laura Rosiñol, Jan Štraub, Aleksandr Suvorov, Carla Araujo, Elena Rimashevskaya, Tomáš Pika, Gianluca Gaïdano, Katja Weisel, Vesselina Goranova‐Marinova, Anthony P. Schwarer, Leonard Minuk, Tamás Masszi, Ievgenii Karamanesht, Massimo Offidani, Vânia Hungria, Andrew Spencer, Robert Z. Orlowski, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng, Wee Joo Chng

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: